US Bancorp’s Day One Biopharmaceuticals DAWN Stock Holding History

US Bancorp’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-414	Closed	-$8.88K	–	4200
2026 Q1	$8.88K	Buy	414 +150	+57%	+$2.11K	﹤0.01%	3393
2025 Q4	$2.46K	Hold	264	–	–	﹤0.01%	3720
2025 Q3	$1.86K	Buy	264 +240	+1,000%	+$1.65K	﹤0.01%	3766
2025 Q2	$156	Buy	24 +4	+20%	+$28	﹤0.01%	4091
2025 Q1	$159	Sell	20 -550	-96%	-$5.92K	﹤0.01%	4102
2024 Q4	$7.22K	Buy	+570	New	+$7.93K	﹤0.01%	3536
2023 Q2	–	Sell	-22,265	Closed	-$298K	–	4021
2023 Q1	$298K	Buy	+22,265	New	+$435K	﹤0.01%	1681

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

US Bancorp's DAWN Position: Q2 2026 in Review

US Bancorp sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 414 shares — an estimated $8.88K sold.

US Bancorp first reported a position in DAWN in Q1 2023 and held it in 7 quarters. The position peaked at $298K in Q1 2023. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

US Bancorp reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 414 Day One Biopharmaceuticals shares in Q2 2026, an estimated $8.88K.
US Bancorp first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 7 quarters.
US Bancorp's Day One Biopharmaceuticals position peaked at $298K in Q1 2023.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.